Challenges and promises of developing thrombin receptor antagonists

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Arterial thrombotic diseases remain a significant unmet medical need despite current dual antiplatelet therapies (aspirin and clopidogrel).
• Thrombin, a potent platelet agonist, plays a critical role in occlusive thrombus formation via protease-activated receptors (PAR-1 and PAR-4).
• PAR-1 is identified as a high-affinity thrombin receptor and a promising novel antithrombotic target.

Purpose of the Study:

• To review the genetic and pharmacological evidence supporting PAR-1 as a validated antithrombotic target.
• To highlight the progress and challenges in developing oral PAR-1 antagonists.
• To present recent advancements in PAR-1 antagonist chemical series.

Main Methods:

• Review of genetic and pharmacological studies on PAR-1.
• Analysis of clinical development progress for PAR-1 antagonists.
• Survey of recent patent literature on novel PAR-1 antagonist chemical series.

Main Results:

• Substantial evidence validates PAR-1 as a key target for antithrombotic therapy.
• Development of oral PAR-1 antagonists, such as SCH 530348 and E-5555, is advancing.
• New chemical series of PAR-1 antagonists have been disclosed in recent patents.

Conclusions:

• Targeting PAR-1 represents a promising strategy for novel antiplatelet therapies.
• Further development of PAR-1 antagonists is crucial for reducing cardiovascular events.
• Ongoing research and patent filings indicate continued innovation in this therapeutic area.